The use of [125i] scintigraphic in vivo imaging in melanoma-bearing mice for a rapid prescreening of vectors to melanoma tissue

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 5, 2009, Pages 629-636

  Miot Noirault, Elisabeth ^a   Papon, Janine ^a   Gardette, Marilyne ^a   Bonnet Duquennoy, Mathilde ^a   Labarre, Pierre ^a   Maisonial, Aurélie ^a   Madelmont, Jean Claude ^a   Maublant, Jean ^a   Chezal, Jean Michel ^a   Moins, Nicole ^a  

^a INSERM   (France)

Author keywords

In vivo planar scintigraphy; Melanoma; Quantitation; Screening; Tumoral uptake; Whole body autoradiography

Indexed keywords

ICF 01011; ICF 01012; ICF 01016; ICF 01035; ICF 01047; IODINE 125; IODINE N (2 DIETHYLAMINOETHYL 7 IODO 9 (4 METHANESULPHONAMIDO 2 METHOXYANILINO)ACRIDINE 4 CARBOXAMIDE I 125; IODINE N (2 DIETHYLAMINOETHYL 9,10 DIHYDRO 7 IODO 9 OXOACRIDINE 4 CARBOXAMIDE I 125; IODINE N (2 DIETHYLAMINOETHYL) 1,4 DIHYDRO 6 IODO 4 OXOQUINOLINE 3 CARBOXAMIDE I 125; IODINE N (2 DIETHYLAMINOETHYL) 7 IODOPHENAZINE 1 CARBOXAMIDE I 125; IODINE N (2-DIETHYLAMINOETHYL) 6 IODOQUINOXALINE 2 CARBOXAMIDE I 125; IODINE N (4 DIPROPYLAMINOBUTYL) 6 IODOQUINOLINE 2 CARBOXAMIDE I 125; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ELIMINATION; GAMMA SCINTIGRAPHY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY ANALYSIS; TISSUE DISTRIBUTION;

ANIMALS; DRUG SCREENING ASSAYS, ANTITUMOR; GENETIC VECTORS; IODINE RADIOISOTOPES; KINETICS; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, CHEMICAL; NEOPLASMS, EXPERIMENTAL; PHANTOMS, IMAGING; RADIONUCLIDE IMAGING; SKIN NEOPLASMS; WHOLE BODY IMAGING;

EID: 70449109984     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0608     Document Type: Article

References (21)

1. Perkins CA, Frier M. Radionuclide imaging in drug development. Curr Pharm Des 2004;10:2907.
2. Solon EG, Balani SK, Lee FW. Whole-body autoradiography in drug discovery. Curr Drug Metab 2002;3:451.
3. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2003;22:151.
4. Pomper MG. Can small animal imaging accelerate drug development? J Cell Biochem 2002;Supplement 39:211.
5. Meikle SR, Eberl S, Iida H. Instrumentation and methodology for quantitative preclinical imaging studies. Curr Pharm Des 2001;7:1945.
6. Rowland DJ, Cherry SR. Small-animal preclinical nuclear medicine instrumentation and methodology. Semin Nucl Med 2008;38:209.
7. Eckelman WC, Waterhouse R, Frank R. Nuclear imaging and biomarkers in drug development using approved radiopharmaceuticals. J Clin Pharmacol 2001;(Suppl 1):4S.
8. Moins N, Papon J, Seguin H, et al. Synthesis, characterization, and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl Med Biol 2001;28:799.
9. Labarre P, Papon J, Moreau MF, et al. Melanin affinity of N- (2-diethylaminoethyl)-4-iodobenzamide, an effective melanoma imaging agent. Melanom Res 2002;12:1115.
10. Moins N, D'Incan M, Bonafous J, et al. 123I-N-(2-diethylaminoethyl)- 2-iodobenzamide: A potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med 2002;29: 1478.
11. Chezal JM, Papon J, Labarre P, et al. Evaluation of radiolabeled (hetero) aromatic analogues of N-(2-diethylaminoethyl)- 4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem 2008;51: 3133.
12. Miao Y, Owen NK, Fisher DR, et al. Therapeutic efficacy of a 188Re-labeled a-melanocyte-stimulating hormone peptide analog in murine and human melanoma-bearing mouse models. J Nucl Med 2005;46:121.
13. Madelmont JC, Chezal JM, Moins N, et al. Labelled analogues of halobenzamides as radiophamraceuticals. French Patent FR2904317, February 1, 2008; WO Patent 2008012782, January 31, 2008.
14. Desbois N, Gardette M, Papon J, et al. Design, synthesis, and preliminary biological evaluation of acridine compounds as potential agents for a combined targeted chemoradionuclide therapy approach to melanoma. Bioorg Med Chem 2008;16: 7671.
15. Labarre P, Papon J, Moreau MF, et al. A new quantitative method to evaluate the biodistribution of a radiolabeled tracer for melanoma using whole-body cryosectioning and a gaseous detector: Comparison with conventional tissue combustion technology. Eur J Nucl Med 1998;25:109.
16. Labarre P, Papon J, Moreau MF, et al. Evaluation in mice of some iodinated melanoma imaging agents using cryosectioning and multi-wire proportional counting. Eur J Nucl Med 1999;26:494.
17. Bissery MC, Guenard D, Gueritte-Voegelein F, et al. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991;51:4845.
18. Beekman FJ, McElroy DP, Berger F, et al. Towards in vivo nuclear microscopy: Iodine-125 imaging in mice using micropinholes. Eur J Nucl Med 2002;29:933.
19. King MA, Pretorius PH, Farncombe T, et al. Introduction to the physics of molecular imaging with radioactive tracers in small animals. J Cell Biochem 2002;39:221.
20. Larsson A, Johansson L, Rossi Norrlund RR, et al. Methods for estimating uptakle and absorbed dose in tumors from 125I-labelled monoclonal antibodies, based on scintigraphic imaging of mice. Acta Oncol 1999;38:361.
21. Carlson SK, Classic KL, Hadac EM, et al. In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography=computed tomography. Mol Imaging Biol 2006;8:324.